Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis

 
• By Jo Shorthouse

Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?

Dandelion
The BREEZE Trials Show Olumiant's Potential In AD • Source: Shutterstock

More from Dermatological

More from Therapy Areas